Two key advances in lung cancer treatment: maintenance therapy extends survival, while an ADC could replace some chemotherapy
Lung cancer experts invited by Goldman Sachs believe Amgen’s Imdelltra combination maintenance therapy could change the standard of care for small-cell lung cancer. An ADC combination from Merck and Kelun-Biotech also shows potential to replace chemotherapy, but global trials are still needed to confirm a survival benefit.
Goldman Sachs ·